علاج سرطان الغدد الليمفاوية التائية المصاحب للوعاء المناعي المتكرر أو المقاوم للعلاج

References

DOI: 10.1016/j.annonc.2025.01.023

• If a clinical trial is not available, platinum-based regimens that are non-cross resistant to the first-line anthracycline-based ChT can be considered [III, B].
• Options for r/r PTCL-NOS and TFHL include ICE, DHAP, GDP, IVAC-MTX and 5-aza (for TFHL only) [III, B].
• Options for patients who are not fit enough for intensive ChT include lenalidomide (not EMA or FDA approved), bendamustine and cyclosporin A [III, B].
• For HSCT-eligible patients responding to salvage therapy, HSCT (preferably allo-HSCT if not used in first line) can be considered [II, B].